GEMZAR + ALIMTA
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Neoplasms
Conditions
Pancreatic Neoplasms, Metastases, Neoplasm
Trial Timeline
โ โ โ
NCT ID
NCT00035035About GEMZAR + ALIMTA
GEMZAR + ALIMTA is a phase 3 stage product being developed by Eli Lilly for Pancreatic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00035035. Target conditions include Pancreatic Neoplasms, Metastases, Neoplasm.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00035035 | Phase 3 | Completed |
Competing Products
20 competing products in Pancreatic Neoplasms